LAB — Standard BioTools Inc.

Summary of Standard BioTools, Inc. Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $40.8 million, down 10% year-over-year, in line with expectations.
• Consumables Revenue: $14.5 million, down 16% year-over-year, impacted by lower volumes and fewer large-scale clinical projects.
• Instruments Revenue: $7.8 million, up 24% year-over-year, driven by strong sales of the Hyperion XTi spatial imaging systems.
• Services Revenue: $17.6 million, down 16% year-over-year, primarily due to a decline in lab services.
• Net Loss: $26 million, improved from a loss of $32.2 million in Q1 2024.
• Adjusted EBITDA: Loss of $16.9 million, improved by 29% from a loss of $23.7 million in Q1 2024.
• Cash Position: $261 million in cash and equivalents, with no material debt. Cash burn reduced to $34 million from $101 million year-over-year.

2. Strategic Updates and Business Highlights

• Continued focus on operational efficiency through the Standard BioTools Business System (SBS), leading to a 22% reduction in non-GAAP operating expenses year-over-year.
• Successful integration of SomaLogic, resulting in over $80 million in cost reductions and improved operational fundamentals.
• New product launches at the AACR conference, including the SomaScan offering and the CyTOF-XT Pro, aimed at enhancing market presence in proteomics.
• Strong partnership with Illumina to expand reach in clinical research, although significant revenue from this partnership is not expected until 2026 and beyond.

3. Forward Guidance and Outlook

• Full-Year Revenue Guidance: Maintained at $165 million to $175 million, with expectations for a back-weighted revenue distribution in 2025.
• Americas Academia Revenue: Anticipated mid-teens percentage decline, reflecting ongoing funding challenges.
• Tariff Impact: Expected to be manageable, with a low single-digit million dollar impact on gross margin and adjusted EBITDA.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Overall revenue decreased due to lower demand in consumables and services, particularly in the Americas academia sector.
• Market Headwinds: Ongoing challenges from NIH budget uncertainties and new tariff measures, which may affect pricing and margins.
• Dependence on Large Customers: Continued reliance on a few large accounts creates variability in quarterly performance.
• Funding Uncertainty: Delays in consumables orders and reduced spending in U.S. academia due to budget constraints.

5. Notable Q&A Insights

• Revenue Split: Management indicated that the revenue split between the first and second halves of the year is expected to be driven more by internal funnel metrics rather than traditional seasonality.
• Instrument Demand: Positive growth in the sales funnel, particularly for the Hyperion XTi, with no significant pull-forward observed.
• M&A Strategy: The company remains committed to pursuing 4-6 strategic acquisitions by 2026, leveraging a favorable cash position to capitalize on market opportunities.
• Biopharma Market: No significant changes in demand patterns were observed in the biopharmaceutical sector, with healthy growth noted despite historical dependence on a few large customers.

Overall, while Standard BioTools faces challenges in revenue generation and market conditions, it is strategically positioned for future growth through operational improvements and new product offerings.